Orexo Reports Q3 2026 Results, DOJ Settlement in Principle and FDA Updates
Orexo said it filed its Q3 2026 interim report, reached a settlement in principle with the DOJ, submitted Izipry to the FDA, and received FDA acceptance of an IND for OX640. BARDA increased funding for OX390 by $2.99 million to $53.8 million total; Orexo also announced an October rights issue.
Orexo AB published its Q3 2026 interim report and said it had reached a settlement in principle with the DOJ. The report also noted FDA submission of Izipry and FDA acceptance of an IND for OX640. BARDA increased funding for OX390 by $2.99M, bringing the total to $53.8M. Orexo also announced an October rights issue.